|1.||Clemens, Andreas: 19 articles (01/2015 - 06/2010)|
|2.||van Ryn, Joanne: 10 articles (08/2015 - 06/2010)|
|3.||Stangier, Joachim: 9 articles (08/2015 - 09/2007)|
|4.||Lip, Gregory Y H: 9 articles (01/2015 - 12/2010)|
|5.||Eriksson, Bengt I: 9 articles (01/2015 - 09/2007)|
|6.||Reilly, Paul A: 8 articles (01/2015 - 09/2009)|
|7.||Friedman, Richard J: 6 articles (01/2015 - 01/2009)|
|8.||Dahl, Ola E: 6 articles (01/2015 - 09/2007)|
|9.||Feuring, Martin: 6 articles (01/2015 - 06/2010)|
|10.||Noack, Herbert: 6 articles (09/2014 - 12/2010)|
01/01/2014 - "Dabigatran etexilate was safe and effective in secondary stroke prevention in clinical practice, including a small number of patients with previous history of CH."
11/15/2014 - "Cardioembolic stroke in a patient taking Dabigatran Etexilate: the first case report of clinical and pharmacologic resistance."
05/01/2014 - "Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry."
01/01/2014 - "We retrospectively included patients starting dabigatran etexilate for secondary stroke prevention from March 2010 to December 2012. "
01/01/2014 - "Our aim was to analyze our clinical experience with dabigatran etexilate in secondary stroke prevention. "
10/01/2013 - "Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature."
11/01/2013 - "Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary."
07/01/2013 - "The objective of the present study was to evaluate, from an economic perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic options available for the protection of moderate-to-high risk patients with non-valvular atrial fibrillation from cardioembolic risk. "
01/01/2012 - "To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. "
11/01/2008 - "Clinical trials of dabigatran etexilate in patients with atrial fibrillation are ongoing. "
04/01/2012 - "This economic evaluation suggests that the use of dabigatran etexilate as a first-line treatment for the prevention of stroke and systemic embolism is likely to be cost-effective in eligible UK patients with AF."
05/01/2011 - "This study demonstrates that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients."
07/01/2013 - "Dabigatran etexilate may represent a cost-effective option for the prevention of thromboembolic events in AF patients at moderate-to-high risk of stroke or systemic embolism."
12/01/2010 - "Indirect evidence suggests treatment with dabigatran etexilate offers benefit for the prevention of stroke, systemic embolism and mortality over antiplatelets and placebo. "
12/01/2010 - "Compared with placebo, dabigatran etexilate 150 mg BID was estimated to significantly reduce the risk of any stroke (ischaemic and haemorrhagic) by 75% (relative risk [RR] 0.25; 95% confidence interval [CI] 0.12-0.51), ischaemic stroke by 77% (RR 0.23; 95% CI 0.14-0.38), systemic embolism by 83% (RR 0.17; 95% CI 0.05-0.50) and mortality by 36% (RR 0.64; 95% CI 0.45-0.91). "
01/01/2009 - "Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). "
10/01/2014 - "Dabigatran etexilate (Pradaxa(®), Prazaxa(®)) has recently been approved for the treatment of acute venous thromboembolism (VTE) and prevention of VTE recurrence. "
10/01/2014 - "Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence."
05/01/2014 - "Dabigatran etexilate for venous thromboembolism: a safety evaluation."
05/07/2012 - "Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery."
10/01/2014 - "However, in the RE-SONATE trial, dabigatran etexilate was associated with a higher risk of bleeding than placebo. "
12/01/2015 - "Idarucizumab received its first global approval, in the USA, in October 2015 for use in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. "
12/01/2015 - "The compounds which have better in vitro and in vivo activity were subjected to rat tail bleeding test, and the result demonstrates that compound I-9 is less likely to have bleeding risk than dabigatran etexilate. "
08/01/2015 - "Those synthesized compounds that have better in vitro activity were subjected to bleeding complication tests, and the results demonstrate that the novel compounds are less likely to have bleeding risk than dabigatran etexilate. "
12/15/2014 - "This is a case report of the fatal course of a 77-year-old bleeding patient in therapy with dabigatran etexilate. "
|6.||Factor Xa (Coagulation Factor Xa)
|3.||Renal Dialysis (Hemodialysis)
|5.||Knee Replacement Arthroplasty (Total Knee Replacement)